the pathogen of his choice—Mycobacterium tuberculosis (M.tb.). TB was a natural choice given the reemerging epidemic that was gaining public attention in the early 1990s and Dr. Barry’s increasing interest in global health. Over the next 5 years, his laboratory focused on understanding some of the basic biochemistry of the cell wall of TB, a rich source of potential drug targets. In 1998, Dr. Barry was tenured as chief of the Tuberculosis Research Section (TBRS) and relocated his laboratory to the main campus of the National Institutes of Health (NIH) in Maryland. In addition to his research group at NIH, with more than 30 members focusing on drug and diagnostic development, he has developed an active clinical research program in South Korea, where he has five ongoing trials with more than 700 participants. Dr. Barry’s group contributed to the development of PA-824, a new drug for TB now in Phase II clinical trials, and developed SQ109, another new TB drug now in Phase Ib trials. Dr. Barry is a member of several editorial boards and has authored more than 130 research publications on TB since entering the field. In 2009 he was named by ScienceWatch as the most highly cited researcher working in the field of TB.
Enriqueta C. Bond, Ph.D., retired in August 2008 as President of the Burroughs Wellcome Fund (BWF), a private foundation whose mission is to advance the medical sciences through the support of research and education. Dr. Bond is a founding partner of QE Philanthropic Advisors and now consults with philanthropic and nonprofit organizations on program development and governance. Previously Dr. Bond served for nearly 20 years as staff officer and division director at the Institute of Medicine, National Academy of Sciences, serving as executive officer from 1989–1994. She serves on numerous board and advisory groups such as the Scientific Advisory Committee on Stewardship for Research on Infectious Diseases of Poverty at WHO’s Program for Research and Training in Tropical Diseases, the NIH Council of Councils, the board and executive committee of the Hamner Institute for Health Sciences, the board of the Health Effects Institute and the James B. Hunt Jr. Institute for Educational Leadership. She currently chairs a National Academies Board on Developing the Capacity of African Academies of Science, is a member of the National Research Council (NRC) Committee on Research Universities, a member of a Task Force on the Organization of the National Academies, and serves as a frequent reviewer of Academy Reports. Dr. Bond previously chaired the Institute of Medicine Clinical Research Roundtable and was a member of the Council of the Eunice Shriver National Institute of Child Health and Human Development. Dr. Bond is a member of the Institute of Medicine and is a fellow of the Association for the Advancement of Science. She was educated at Wellesley College (A.B.), the University of Virginia (M.A.), and Georgetown University (Ph.D.) in genetics and molecular biology.